Manaka Hiroya, Igawa Satoshi, Yamamoto Michiko, Oguri Akito, Manabe Hideaki, Kasajima Masashi, Kusuhara Seiichiro, Hosotani Shinji, Nakahara Yoshiro, Sato Takashi, Fukui Tomoya, Hisashi Mitsufuji, Sasaki Jiichiro, Naoki Katsuhiko
Department of Respiratory Medicine, Kitasato University School of Medicine, 1-15-1, Kitasato, Minami-ku, Sagamihara-city, Kanagawa, 252-0374, Japan.
Department of Respiratory Medicine, Kanagawa Prefectural Federation of Agricultural Cooperatives for Health and Welfare Sagamihara Kyodo Hospital, Sagamihara-city, Kanagawa, Japan.
Invest New Drugs. 2023 Feb;41(1):115-121. doi: 10.1007/s10637-023-01327-w. Epub 2023 Jan 12.
Thymic carcinoma is a very rare neoplasm for which no optimal chemotherapeutic regimen has been established to date. Hence, we performed this study to investigate the efficacy and safety of carboplatin plus nanoparticle albumin-bound (nab)-paclitaxel as a first-line regimen for patients with advanced thymic carcinoma. We conducted this multi-institutional retrospective cohort study of patients with advanced thymic carcinoma who had received carboplatin plus nab-paclitaxel as a first-line chemotherapy between August 2013 and December 2021. Twelve patients were included in this study and were subjected to efficacy and safety analysis. Their median age was 62 years (range, 47-74 years), and all had an Eastern Cooperative Oncology Group performance status score of 0 or 1. After a median follow-up time of 19.7 months, the overall response rate was 50%; the median progression-free and overall survival times were 8.8 months and 23.3 months, respectively. Chemotherapy-related peripheral neuropathy was observed in 2 patients (16%; each with grade 1). Other toxicities were manageable, and there were no treatment-related deaths. Carboplatin plus nab-paclitaxel as a first-line chemotherapy regimen showed good efficacy and safety in patients with advanced thymic carcinoma.
胸腺癌是一种非常罕见的肿瘤，迄今为止尚未确立最佳的化疗方案。因此，我们开展了本研究，以调查卡铂联合纳米白蛋白结合型（nab）紫杉醇作为晚期胸腺癌患者一线治疗方案的疗效和安全性。我们对2013年8月至2021年12月期间接受卡铂联合nab紫杉醇作为一线化疗的晚期胸腺癌患者进行了这项多机构回顾性队列研究。本研究纳入了12例患者，并对其进行疗效和安全性分析。他们的中位年龄为62岁（范围47 - 74岁），所有患者东部肿瘤协作组体能状态评分为0或1。中位随访时间为19.7个月后，总缓解率为50%；中位无进展生存期和总生存期分别为8.8个月和23.3个月。2例患者（16%；均为1级）出现化疗相关的周围神经病变。其他毒性反应可控制，且无治疗相关死亡。卡铂联合nab紫杉醇作为一线化疗方案在晚期胸腺癌患者中显示出良好的疗效和安全性。
